Literature DB >> 3917374

Control of VX2 carcinoma cell growth in culture by calcium, calmodulin, and prostaglandins.

T Yoneda, M Kitamura, T Ogawa, S Aya, M Sakuda.   

Abstract

Based on our in vivo observation that growth of VX2 carcinoma transplanted in rabbits paralleled development of hypercalcemia, we studied the regulation of VX2 tumor growth using a clonal cell line isolated from VX2 tumor (VX2-L). VX2-L cell growth was dependent on prostaglandins released by the cultured cells into the medium, since indomethacin suppressed VX2-L growth, and prostaglandins A2, E1, E2, F1 alpha, and F2 alpha stimulated VX2-L proliferation. In contrast, prostaglandins D2 and I2 inhibited VX2-L proliferation. In contrast to previous reports, increases in extracellular calcium concentration promoted VX2-L growth not only directly but indirectly through augmentation of prostaglandin E synthesis. Antagonists of the intracellular calcium binding protein calmodulin inhibited cell replication. Increases in extracellular calcium also stimulated production of a nonprostaglandin macromolecular bone-resorbing factor. This factor may account for the hypercalcemia which we were unable to block by indomethacin. These results suggest a close relationship between VX2-L growth, prostaglandin production, and hypercalcemia. It is proposed that calcium blockers and anticalmodulin drugs might be powerful anticancer and/or antihypercalcemic agents for malignant cells such as VX2-L.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Calcium antagonists and cancer. Is there really a link?

Authors:  L G Howes; C T Edwards
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

2.  Role of 1,25-dihydroxyvitamin D3 and extracellular calcium in the regulation of proliferation in cultured SH-SY5Y human neuroblastoma cells.

Authors:  A Celli; C Treves; P Nassi; M Stio
Journal:  Neurochem Res       Date:  1999-05       Impact factor: 3.996

3.  Near-infrared Transillumination and Photodynamic Therapy Using Hypericin in Animal Laryngeal Tumors.

Authors:  Haeyoung Lee; Sung Won Kim; Daa Young Kwon; Hyun Wook Kang; Min-Jung Jung; Jun Hyeong Kim; Yeh-Chan Ahn; Chulho Oak
Journal:  Tissue Eng Regen Med       Date:  2021-09-08       Impact factor: 4.451

4.  Oral diclofenac combined with intra-portal pirarubicin: increased efficacy on liver VX2 tumour and hepatotoxicity in rabbits.

Authors:  B Donatini; C Bognel; J N Munck; L Ramirez; P Ardouin; P Rougier
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 5.  Diverse effects of essential (n-6 and n-3) fatty acids on cultured cells.

Authors:  S I Grammatikos; P V Subbaiah; T A Victor; W M Miller
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

6.  Calcium antagonism by the antioestrogen tamoxifen.

Authors:  A Lipton; I D Morris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Doxorubicin treatment of rabbit renal VX-2 carcinoma: nephrotoxicity, serum parameters and weight.

Authors:  G Gadeholt-Göthlin; H Vik; J H Göthlin
Journal:  Urol Res       Date:  1995

8.  Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.

Authors:  Ron C Gaba; Ramzy C Khabbaz; Ruth N Muchiri; Joseph D Morrison; Lobna Elkhadragy; William M Totura; Jonathan P Samuelson; Herbert E Whiteley; Ryan L Deaton; Peter L Nguyen; Maria Sverdlov; Jeremy J Johnson; Richard B van Breemen; R Peter Lokken
Journal:  Drug Deliv Transl Res       Date:  2021-04-16       Impact factor: 4.617

9.  Simultaneous hyperthermia-chemotherapy effect by arterial injection of Fe(Salen) for femur tumor.

Authors:  Masanari Umemura; Md Rafikul Islam; Hidenobu Fukumura; Itaru Sato; Yusuke Kawabata; Kousuke Matsuo; Rina Nakakaji; Akane Nagasako; Makoto Ohtake; Fujita Takayuki; Utako Yokoyama; Tomohiro Nakayama; Haruki Eguchi; Yoshihiro Ishikawa
Journal:  Cancer Sci       Date:  2018-12-06       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.